BioMed stocks in motion: PDSB, NMLSF, TNXP, AIMLF;

NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) — Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from the CEOs of: Tonix Pharmaceuticals (NASDAQ: TNXP), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PDS Biotechnology (NASDAQ: PDSB) and AI/ML Innovations (OTC: AIMLF) (CSE: AIML). As the global pharmaceutical market surpasses $1.3 trillion (Statista), emerging technologies and healthcare research innovations are unlocking new opportunities for exponential growth. As the biotech sector rebounds from cyclical lows, institutional investors are increasingly eyeing early-stage biotech stocks for alpha-generating upside potential. The Wall Street Reporter highlights the latest comments from industry thought leaders who are shaping our world today and in the decades to come:

Frank Bedu-Addo, CEO of PDS Biotechnology (NASDAQ: PDSB): “FDA Fast-Track Highlights Potential of Versamune Platform”
PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing a growing portfolio of molecular-targeted cancer immunotherapies and infectious disease vaccines based on proprietary Versamune® T-cell activation technologies and The company’s Infectimune™, today announced that the United States Drug Administration (FDA) has granted Fast Track Designation to PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). PDS0101 in combination with KEYTRUDA® is being studied in the multicenter, open-label, Phase 2 VERSATILE-002 trial for the treatment of recurrent or metastatic HPV16 positive head and neck cancer in collaboration with Merck. PDSB CEO Frank Bedu-Addo, Ph.D said, “We are delighted that the FDA has granted Fast Track Designation for PDS0101 in combination with KEYTRUDA®. The prevalence of HPV-associated head and neck cancer continues to rise, leaving this affected group with limited treatment options to date. Receiving this designation underscores the potential of the Versamune® platform and the need for a new therapy that could improve outcomes for people with this devastating disease.
PDS Biotechnology (NASDAQ: PDSB) NEWS:

Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, MD: “Nova Psilocybin-based therapeutic showing great promise for autism and Othe Neuro-inflammatory disorders »
Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), a guest presenter at Wall Street Reporter’s NEXT SUPER STOCK investor conference, is advancing new psilocybin therapies, targeting autism spectrum disorders, a need unmet medical device with multi-billion dollar market potential. NMLSF’s Chief Medical Officer, Dr. Marvin Hausman, MD, has decades of success promoting new drugs through FDA regulatory pathways, through to commercialization, generating billions of dollars in revenue. Dr. Hausman is now bringing the “same playbook” to NMLSF for his psilocybin therapies targeting Fragile X, and then potential expansion to treat other neuroinflammatory disorders, including Alzheimer’s and Parkinson’s. The NMLSF plans to submit a clinical trial application to Health Canada for a Phase 2A study evaluating its psilocybin microdose therapy for fragile X syndrome in the coming weeks.

NMLSF is a world leader in first-class psilocybin therapies and complementary diagnostics for neuroinflammatory disorders. NMLSF is the first biotechnology company to obtain “Orphan Drug Designation” from the FDA in the United States and European Union for the use of psilocybin in the treatment of FXS. In his interview with The Wall Street Reporter, Dr. Hausman explains his strategy for advancing NMLSF’s drug pipeline through commercialization, as he has successfully done with other new drugs over his decades-long career. .
Watch the NEXT SUPER STOCK Nova Mentis (OTC: NMLSF) (CSE: NOVA) video:

“The recently completed preclinical study of repeating low doses of our psilocybin drug – every other day for 2 weeks, showed clinical responses that far exceeded our expectations. We significantly modulated behavioral and cognitive defects , such as recognition memory, in the FXS.” The NMLSF plans to submit a clinical trial application to Health Canada in the coming weeks for a Phase 2A study evaluating psilocybin microdose therapy for FXS. “Autism Spectrum Disorders (“ASD”) and in particular FXS, the largest genetic cause of ASD, continue to have unmet medical needs. NOVA scientists over the past two years have cast the groundwork for the development of a potential new psilocybin-based microdose treatment for ASD,” said NMLSF Chief Medical Officer Dr. Marvin S. Hausman, MD.
Watch the NEXT SUPER STOCK Nova Mentis (OTC: NMLSF) (CSE: NOVA) video:

AI/ML Innovations (OTC: AIMLF) (CSE: AIML) Chairman, Tim Daniels: “AI/ML holds key patents for a multi-billion dollar market in wearable healthcare devices”
AI/ML Innovations (OTC: AIMLF), a featured presenter on Wall Street Reporter’s “Next Super Stock” investor conference series, recently briefed investors on digital health portfolio growth initiatives from AIMLF, including HealthGauge, a wearable personal health monitoring and management system, using artificial intelligence and machine learning, and Tech2Heal, a European innovator in mental health apps.

AIMLF’s landmark patent position for wearable health monitors is of significant interest to investors – who could position AIMLF to collect licensing fees and royalties on 13 global smart wearable health devices $.8 billion (expected to grow to $37.4 billion by 2028. Source: Verified Market Research.) AIMLF is now beginning to license its technologies to healthcare apparel companies and collect royalties. With typical royalties of 2% of gross sales, the AIMLF could potentially generate significant recurring revenue from companies infringing on its broad patent position in the nearly $14 billion healthcare apparel market.
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:

AIMLF’s Health Gauge subsidiary recently obtained a patent from the United States Patent and Trademark Office (US Patent No. 11183303), entitled “Wearable Health Monitors and Methods of Monitoring Health”. The patent covers cardiovascular monitoring, predictive health analytics, behavioral analytics, and 64 other claims, including the use of multiple wearable health monitor configurations, in conjunction with biological signal analysis methods and health metrics monitoring (via Health Gauge AI-based software) to help the user achieve their personal health and wellness goals.

AIMLF reports ramping growth in its portfolio company Tech2Heal, a European innovator in mental health apps. Tech2Heal is positioned for explosive revenue growth as European healthcare mandates now provide around €2,500 per patient per year for mental well-being. Tech2Heal has just signed with a French multinational manufacturer, to provide mental wellness support to its 170,000 employees worldwide, and further corporate contracts are in the pipeline. Tim Daniels also updated investors on AIML’s growing pipeline of health technology M&A opportunities, which could have a positive impact on maximizing shareholder value in the months ahead. .
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:

Seth Lederman, MD, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP): “Expanding the Vaccine Pipeline”
Tonix Pharmaceuticals (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced United States Patent and Trademark Office Patent No. 11,345,896 to the Company on May 31, 2022, titled “Synthetic Chimeric Poxviruses includes claims covering synthetic horse pox virus, the basis for the company’s TNX-8011 vaccine being developed to protect against monkeypox and smallpox and for the company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2. This patent is expected to grant Tonix exclusivity in the US market until 2037, excluding any patent term extension or patent term adjustment.
TNXP CEO Seth Lederman, MD said, “This patent is an important step in protecting our expanding pipeline of vaccines that address known and potentially new pathogens. smallpox. TNX-18401 and TNX-18501 are engineered to express SARS-CoV-2 variant spike proteins omicron and BA.2, respectively. Horsepox was one of the first viruses ever generated by synthetic biology and remains among the most important.
Tonix Pharmaceuticals (NASDAQ: TNXP) NEWS:


Wall Street Reporter (est. 1843) is the leading provider of financial information, focused on giving investors direct access to CEOs of promising publicly traded companies and market experts. Nothing in this news summary should be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer and relevant SEC 17B disclosures here:

About Wall Street Reporter’s Next Super Stock conference:

NEXT SUPER STOCK live from The Wall Street Reporter! The conference is dedicated to showcasing select companies that have put in place near-term catalysts that can drive transformational growth (and stock appreciation) in the months ahead. Click here to join the next live stream event:



(212) 871-2057 ext 7

About Larry Noble

Check Also

Stock to buy: This multibagger IT stock is top pick for November, brokerage sees 20% returns, buy

Outlook and stock returns INFO is one of the leading large cap IT companies in …